Allinaire Therapeutics

Allinaire Therapeutics is a privately held, clinical-stage biotechnology company headquartered in Cleveland, Ohio. Founded in 2016 by BioMotiv with technology licensed from Indiana University, the company is focused on developing novel, disease-modifying therapeutics for cardiopulmonary diseases. Allinaire's core scientific platform is built around... humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies. EMAP II is a non-classical cytokine that plays a pivotal pathogenic role in apoptosis, cell injury, endothelial cell function, and inflammation. The company's therapeutic candidates are being developed to address pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury conditions representing significant unmet medical needs. Allinaire's research is grounded in the pioneering work of scientific co-founders Matthias Clauss, PhD, and Irina Petrache, MD, from Indiana University and National Jewish Health, and is supported by a network of preclinical and clinical scientists. The company has received funding from investors including Elevate Ventures, BioCrossroads, and the National Heart, Lung, and Blood Institute.Read More